Author

S. Kauppinen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:metagenomics· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

A. Azimi· 1 shared A. M. Näär· 1 shared A. Petri· 1 shared A. Rustagi· 1 shared A. S. Rahmanto· 1 shared B. A. Pinsky· 1 shared C. A. Blish· 1 shared C. Chiu· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Azimi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An intranasal ASO therapeutic targeting SARS-CoV-2

C. Zhu, J. Y. Lee, J. Z. Woo, L. Xu, X. Nguyenla, L. H. Yamashiro, F. Ji, S. B. Biering, E. V. Dis, F. Gonzalez, D. Fox, A. Rustagi, B. A. Pinsky, C. A. Blish, C. Chiu, , A. M. Näär

This paper develops an intranasal ASO therapy targeting SARS-CoV-2 RNA that effectively prevents viral replication in multiple models and variants.

bioRxiv · May 17, 2021Microbiology

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

L. Vidarsdottir, A. Azimi, I. Sigvaldadottir, A. S. Rahmanto, A. Petri, S. Kauppinen, C. Ingvar, G. Jonsson, H. Olsson, M. Frostvik-Stolt, R. Tuominen, O. Sangfelt, K. Pokrovskaja, J. Hansson, D. Grander, , P. Johnsson

This study shows that PTENP1-AS contributes to BRAF inhibitor resistance and is linked to poor clinical outcomes in stage III melanoma.

bioRxiv · May 3, 2020Cancer Biology